Medication Use Evaluation - NAPLEX

1. A pharmacy-led MUE reviews monitoring for hepatotoxicity in a 61-year-old female (weight 72 kg) treated for latent tuberculosis infection. Medications: isoniazid 300 mg daily plus pyridoxine 25 mg daily (started 6 weeks ago; adherent), and atorvastatin 20 mg nightly; she reports new fatigue and decreased appetite. Labs: AST 145 U/L (10–40), ALT 172 U/L (7–56), total bilirubin 1.8 mg/dL (0.2–1.2), SCr 0.9 mg/dL (0.6–1.2). The goal is safe completion of therapy while preventing severe liver injury. What monitoring parameter is most critical for this patient's therapy?
   Answer: Serial liver function tests (AST/ALT and bilirubin) with symptom assessment for hepatitis This question tests medication use evaluation for monitoring drug-induced hepatotoxicity in tuberculosis treatment. The key patient-specific factors are new fatigue, decreased appetite, and elevated LFTs (AST 145 U/L, ALT 172 U/L, bilirubin 1.8 mg/dL) after 6 weeks of isoniazid, indicating potential hepatotoxicity. Serial liver function tests with symptom assessment is most critical to detect and manage hepatitis early, allowing therapy continuation if reversible. Weekly potassium is irrelevant as isoniazid does not cause hyperkalemia; daily INR is unnecessary without anticoagulation; amylase/lipase target pancreatitis, not primary isoniazid toxicity. A clinical pearl is to monitor LFTs baseline and periodically (e.g., every 2-4 weeks) for isoniazid, stopping if ALT >3x ULN with symptoms. In similar scenarios, establish monitoring frequency based on risk (e.g., age >50), interpret trends, and hold therapy if severe.
2. A medication reconciliation MUE identifies duplicate therapy in a 38-year-old female (weight 70 kg) admitted for migraine with nausea. Home meds: sertraline 100 mg daily and sumatriptan 50 mg as needed (uses 2 doses/week). Inpatient orders include sumatriptan 6 mg subcutaneously now, and linezolid 600 mg IV every 12 hours started for suspected pneumonia; she becomes agitated with tremor and diaphoresis. Vitals: HR 112 bpm, BP 158/92 mmHg, temperature 38.3°C; labs: SCr 0.8 mg/dL (0.6–1.2). How should the pharmacist address the identified drug interaction?
   Answer: Recommend avoiding concurrent linezolid with serotonergic agents when possible, contacting the prescriber for an alternative antibiotic or holding sertraline with close monitoring This question tests medication use evaluation for managing serotonergic drug interactions during medication reconciliation. The key patient-specific factors are symptoms of agitation, tremor, diaphoresis, tachycardia, and hypertension, with concurrent linezolid, sertraline, and sumatriptan, all increasing serotonin. Recommending avoidance of concurrent use, prescriber contact for alternatives, and monitoring is the best choice to prevent serotonin syndrome while treating underlying conditions. Continuing without changes risks escalation; increasing sertraline worsens symptoms; adding dextromethorphan adds serotonergic risk. A clinical pearl is that linezolid's MAO inhibition amplifies SSRI/triptan effects; hold serotonergics if possible. In similar scenarios, recognize syndrome criteria (e.g., Hunter), de-escalate promptly, and select non-serotonergic options like vancomycin for infection.
3. During a quarterly medication use evaluation (MUE), a community pharmacy reviews a 58-year-old male (weight 96 kg) with type 2 diabetes and ASCVD whose last 3 months of refill history shows metformin ER 1000 mg PO twice daily (misses ~4 doses/week), insulin glargine 30 units subcutaneously nightly (misses ~2 injections/week), and atorvastatin 80 mg PO daily (adherent); he reports fasting self-monitored blood glucose often 180–240 mg/dL. Labs: A1c 10.2% (goal <7%), SCr 1.0 mg/dL (0.6–1.3), eGFR 88 mL/min/1.73 m$^2$ (≥60), ALT 28 U/L (7–56). The pharmacy manager wants the pharmacist to implement an intervention that most directly improves glycemic outcomes by addressing the primary driver identified in the MUE. What is the best strategy to improve patient adherence?
   Answer: Initiate a pharmacist-led adherence plan: simplify to once-daily metformin ER 2000 mg with dinner if tolerated, provide injection technique counseling, set refill synchronization, and enroll the patient in SMS reminders with follow-up in 2 weeks This question tests medication use evaluation for identifying and addressing medication non-adherence as a primary driver of poor glycemic control. The key patient-specific factor is the documented pattern of missed doses for both metformin (4 doses/week) and insulin glargine (2 injections/week), which directly correlates with the elevated A1c of 10.2% and fasting glucose values of 180-240 mg/dL. Option B is the best choice because it comprehensively addresses adherence barriers through multiple evidence-based strategies: simplifying the metformin regimen to once-daily extended-release formulation, providing injection technique counseling, implementing refill synchronization, and utilizing technology-based reminders with short-term follow-up. Option A incorrectly adds another medication without addressing the underlying adherence problem, which would likely fail given the patient's current non-adherence pattern. Option C inappropriately discontinues basal insulin in a patient with A1c >10%, which could worsen glycemic control and potentially precipitate hyperglycemic crisis. Option D simply increases the insulin dose without addressing adherence, which could increase hypoglycemia risk when the patient does take doses while failing to improve overall control. The clinical pearl is that medication non-adherence must be identified and systematically addressed before intensifying therapy, as adding medications to a non-adherent patient rarely improves outcomes.
4. A community pharmacy performs an MUE on diabetes control for a 52-year-old male (weight 102 kg) with type 2 diabetes and hypertension. Medication history: metformin ER 1000 mg twice daily (adherent), glipizide XL 10 mg daily (misses 2–3 doses/week), and lisinopril 20 mg daily; he reports 2 episodes of shakiness relieved by juice in the last month. Labs: A1c 9.2% (goal <7%), fasting glucose 190 mg/dL (70–99), serum creatinine 0.9 mg/dL (0.6–1.2), ALT 28 U/L (7–56). The pharmacy's therapeutic goal is improved glycemic control while reducing hypoglycemia risk. Which medication change is most appropriate to improve therapeutic outcomes?
   Answer: Discontinue glipizide and initiate semaglutide 0.25 mg subcutaneously weekly with titration as tolerated This question tests medication use evaluation for optimizing glycemic control in type 2 diabetes while addressing hypoglycemia and adherence issues. The key patient-specific factors are the patient's A1c of 9.2%, fasting glucose of 190 mg/dL, episodes of hypoglycemia, nonadherence to glipizide, and overweight status (102 kg). Discontinuing glipizide and initiating semaglutide is the best choice as it reduces hypoglycemia risk, promotes weight loss, and improves A1c with once-weekly dosing to enhance adherence. Increasing glipizide to 20 mg daily is suboptimal as it heightens hypoglycemia risk without addressing adherence; stopping metformin to start pioglitazone ignores metformin's first-line status and pioglitazone's risks like heart failure; adding sliding-scale insulin alone fails to provide basal coverage and increases complexity. A clinical pearl is to prioritize agents with low hypoglycemia risk like GLP-1 receptor agonists in overweight patients with sulfonylurea-related issues. In similar scenarios, evaluate A1c against goals, assess adherence barriers, and select therapies balancing efficacy, safety, and patient preferences.
5. A formulary management MUE at a managed care pharmacy evaluates therapeutic substitution for a 59-year-old male (weight 90 kg) with GERD and a history of erosive esophagitis. Current therapy: esomeprazole 40 mg by mouth daily (adherent) with symptom control; other meds include atorvastatin 20 mg nightly and hydrochlorothiazide 25 mg daily. The plan will no longer cover esomeprazole and prefers omeprazole and pantoprazole; labs show magnesium 1.8 mg/dL (1.7–2.2) and normal LFTs/SCr. The goal is to maintain symptom control with an evidence-based, cost-effective alternative. Which medication change is most appropriate to improve therapeutic outcomes?
   Answer: Switch to pantoprazole 40 mg by mouth daily as a therapeutically equivalent PPI alternative This question tests medication use evaluation for therapeutic substitution in GERD management under formulary constraints. The key patient-specific factors are history of erosive esophagitis requiring high-dose PPI for healing, current symptom control with esomeprazole 40 mg, and formulary preference for omeprazole or pantoprazole. Switching to pantoprazole 40 mg daily is the best choice as it provides equivalent potency and efficacy for erosive disease at a cost-effective dose. Switching to famotidine 10 mg is suboptimal due to lower efficacy for erosive esophagitis compared to PPIs; stopping PPI abruptly risks rebound symptoms; omeprazole 10 mg is underdosed for maintenance in erosive cases. A clinical pearl is that PPIs like pantoprazole and omeprazole are therapeutically interchangeable at equipotent doses (e.g., 40 mg). In similar scenarios, confirm disease severity, match doses for equivalence, and monitor symptoms post-substitution.
6. A pharmacist reviews a high-alert medication MUE for insulin safety in a 72-year-old female (weight 64 kg) with type 2 diabetes and stage 3 chronic kidney disease. Home meds: insulin glargine 30 units nightly (often takes 30–40 units based on bedtime glucose), insulin lispro 10 units with meals (skips when not eating), and glyburide 5 mg daily; labs: A1c 7.1% (goal individualized 7–8%), SCr 1.6 mg/dL (0.6–1.2), eGFR 32 mL/min/1.73 m$^2$ (>60). She reports 3 episodes of morning glucose <60 mg/dL (70–99) in the past 2 weeks. Which medication change is most appropriate to improve therapeutic outcomes?
   Answer: Discontinue glyburide and standardize basal insulin dosing with a lower fixed glargine dose plus education on hypoglycemia management This question tests medication use evaluation for insulin safety and hypoglycemia prevention in elderly patients with CKD. The key patient-specific factors are recurrent hypoglycemia (<60 mg/dL), variable glargine dosing, glyburide use, and reduced eGFR (32 mL/min/1.73 m²), increasing sulfonylurea hypo risk. Discontinuing glyburide and standardizing fixed lower glargine with education is the best choice to reduce variability and hypo events while maintaining control. Increasing glyburide worsens hypo; advising to skip breakfast is unsafe; switching to NPH adds peak-related risks. A clinical pearl is to avoid long-acting sulfonylureas in CKD due to prolonged effects; use fixed basal insulin. In similar scenarios, review glucose logs, eliminate high-risk agents, educate on consistent dosing, and monitor A1c for adjustments.
7. A medication safety MUE reviews QT-prolonging combinations for a 49-year-old female (weight 66 kg) treated for nausea and depression. Current meds: citalopram 40 mg daily (adherent), hydrochlorothiazide 25 mg daily, and new ondansetron 8 mg by mouth every 8 hours as needed (used 3 doses/day). ECG shows QTc 510 ms (normal <450), and labs show potassium 3.2 mEq/L (3.5–5.0) and magnesium 1.6 mg/dL (1.7–2.2); SCr 0.8 mg/dL (0.6–1.2). The goal is to reduce torsades de pointes risk while maintaining symptom control. How should the pharmacist address the identified drug interaction?
   Answer: Recommend correcting electrolytes, limiting QT-prolonging agents (e.g., reduce citalopram dose or change antidepressant and use alternative antiemetic), and repeat ECG This question tests medication use evaluation for addressing QT-prolonging drug interactions. The key patient-specific factors are prolonged QTc (510 ms), low potassium (3.2 mEq/L) and magnesium (1.6 mg/dL), and multiple QT-prolongers (citalopram, ondansetron, hydrochlorothiazide). Recommending electrolyte correction, reducing QT agents (e.g., lower citalopram or alternatives), and repeat ECG is the best choice to minimize torsades risk while controlling symptoms. Continuing without changes ignores arrhythmia risk; increasing ondansetron worsens QT prolongation; adding azithromycin adds another QT-prolonger. A clinical pearl is to use CredibleMeds for QT risk assessment and correct modifiable factors first. In similar scenarios, review ECG and electrolytes, prioritize deprescribing high-risk drugs, and monitor QTc serially.
8. A pharmacist conducts an adverse-effect focused MUE for a 63-year-old male (weight 84 kg) with chronic kidney disease stage 3a and diabetic neuropathy. Current meds: gabapentin 900 mg PO three times daily (often takes all 3 doses together at bedtime), metformin 1000 mg PO twice daily (adherent), lisinopril 10 mg PO daily (adherent), and diphenhydramine 50 mg PO nightly for sleep (most nights). Labs: SCr 1.7 mg/dL (0.6–1.3), eGFR 42 mL/min/1.73 m$^2$ (≥60), A1c 7.4% (goal <7% individualized). He reports daytime sedation, dizziness, and 2 falls in the last month. What is the most likely cause of the patient's symptoms?
   Answer: Additive central nervous system depression from high-dose gabapentin (with dose stacking) combined with diphenhydramine, worsened by reduced renal clearance This question tests adverse effect identification in the context of inappropriate dosing and drug combinations in chronic kidney disease. The key patient-specific factors are gabapentin 900 mg three times daily (often taken all at once) in a patient with eGFR 42 mL/min/1.73 m², combined with nightly diphenhydramine use, presenting with sedation, dizziness, and falls. Option A correctly identifies that gabapentin requires dose reduction in CKD stage 3a (typical max 300-600 mg three times daily), and taking all doses together creates dose stacking with prolonged CNS depression, which is potentiated by the anticholinergic effects of diphenhydramine. Option B is incorrect because metformin doesn't cause hypoglycemia as monotherapy, and taking it with meals is the correct administration method. Option C is implausible as lisinopril rarely causes hepatotoxicity, and the normal liver enzymes contradict this mechanism. Option D is incorrect because the A1c of 7.4% and absence of typical DKA symptoms (no mention of acidosis, ketones, or severe hyperglycemia) make this diagnosis impossible. The clinical pearl is that gabapentin accumulates in renal dysfunction and requires dose adjustment based on eGFR, while concurrent CNS depressants multiply the risk of sedation and falls in older adults.
9. An inpatient pharmacy conducts an adverse-effect MUE after several cases of oversedation. A 70-year-old male (weight 80 kg) admitted for pneumonia has COPD and chronic pain; current inpatient meds include oxycodone 10 mg by mouth every 4 hours scheduled, gabapentin 600 mg three times daily (home med, adherent), and new lorazepam 1 mg by mouth every 6 hours as needed for anxiety (received 3 doses in 24 hours). He is somnolent with respiratory rate 10/min (12–20) and oxygen saturation 90% on 2 L; labs: serum creatinine 1.0 mg/dL (0.6–1.2), AST/ALT normal. The goal is to reduce medication-related respiratory depression while maintaining symptom control. What is the most likely cause of the patient's symptoms?
   Answer: Additive CNS and respiratory depression from concurrent opioid, benzodiazepine, and gabapentin use This question tests medication use evaluation for identifying causes of adverse effects like oversedation in polypharmacy. The key patient-specific factors are somnolence, respiratory depression (rate 10/min, SpO2 90%), and concurrent use of oxycodone, gabapentin, and lorazepam, all CNS depressants. Additive CNS and respiratory depression from this combination is the most likely cause, as opioids, benzodiazepines, and gabapentin synergistically impair respiration. Serotonin syndrome is unlikely without serotonergic symptoms like hyperreflexia; acute adrenal insufficiency does not fit short-term lorazepam use; hypertensive crisis contradicts the sedation presentation. A clinical pearl is that combining opioids with benzodiazepines or gabapentinoids significantly increases overdose risk per CDC guidelines. In similar scenarios, review medication lists for CNS depressants, assess vital signs, and de-escalate by tapering or substituting to minimize risks while controlling symptoms.
10. A hospital discharge MUE focuses on opioid stewardship for a 40-year-old male (weight 78 kg) after laparoscopic cholecystectomy. Discharge prescriptions: oxycodone 5 mg by mouth every 4 hours as needed (#30), acetaminophen 1000 mg every 6 hours scheduled, and ibuprofen 600 mg every 6 hours scheduled; he also takes clonazepam 0.5 mg nightly (adherent) for anxiety. Labs: SCr 0.9 mg/dL (0.6–1.2), AST/ALT normal; pain is rated 3/10 at rest. The goal is to reduce overdose risk and align with safe prescribing practices. How should the pharmacist address the identified drug interaction?
    Answer: Recommend limiting opioid quantity/duration, counsel on avoiding concurrent benzodiazepine use when taking opioids, and offer naloxone per protocol This question tests medication use evaluation for opioid stewardship and interaction management at discharge. The key patient-specific factors are post-surgical opioid prescription with concurrent clonazepam (a benzodiazepine), increasing overdose risk, and low pain (3/10). Recommending limited opioid quantity, counseling against concurrent use, and offering naloxone is the best choice to align with safe practices and reduce harm. Dispensing as written with diphenhydramine adds sedation; increasing oxycodone escalates risk; stopping acetaminophen limits multimodal pain control. A clinical pearl is that opioids plus benzodiazepines amplify respiratory depression; limit to <50 MME/day post-op. In similar scenarios, calculate MME, assess interactions, provide education and naloxone, and follow up on usage.
11. During a warfarin MUE in an anticoagulation clinic, a 58-year-old female (weight 68 kg) with a mechanical mitral valve is reviewed for unstable INR. Medications: warfarin 5 mg nightly (takes as directed), amiodarone 200 mg daily (started 2 weeks ago), and acetaminophen 1000 mg three times daily for arthritis (daily). Labs: INR 4.6 (goal 2.5–3.5), hemoglobin 12.8 g/dL (12–16), AST/ALT normal, serum creatinine 0.9 mg/dL (0.6–1.2); no bleeding symptoms. How should the pharmacist address the identified drug interaction?
    Answer: Recommend holding one warfarin dose and reducing the maintenance dose with closer INR monitoring due to amiodarone interaction This question tests medication use evaluation for managing warfarin drug interactions in anticoagulation clinics. The key patient-specific factors are supratherapeutic INR (4.6, goal 2.5-3.5), recent amiodarone initiation (potentiates warfarin via CYP inhibition), and no bleeding. Recommending to hold one dose, reduce maintenance, and monitor INR closely is the best choice to safely correct over-anticoagulation while accounting for the interaction's delayed onset. Increasing warfarin ignores the interaction and risks bleeding; continuing without adjustment prolongs supratherapeutic state; stopping amiodarone without input disrupts arrhythmia control. A clinical pearl is that amiodarone-warfarin interaction requires 25-50% dose reduction with weekly INR checks. In similar scenarios, calculate interaction impact (e.g., onset 1-2 weeks), adjust dose empirically, and monitor INR frequently to guide further changes.
12. A long-term care consultant pharmacist performs an MUE on proton pump inhibitor (PPI) deprescribing in an 82-year-old female (weight 54 kg) with osteoporosis and a remote history of GERD. Medications: omeprazole 20 mg daily for 3 years (no current heartburn), alendronate 70 mg weekly, calcium/vitamin D daily, and acetaminophen as needed; adherence is consistent. Labs: magnesium 1.7 mg/dL (1.7–2.2), vitamin B12 260 pg/mL (200–900), SCr 0.8 mg/dL (0.6–1.2). The goal is to minimize unnecessary chronic PPI exposure while maintaining symptom control. What is the best approach to optimize this patient's therapy?
    Answer: Taper and discontinue omeprazole with a plan for on-demand therapy if symptoms recur and monitor for rebound symptoms This question tests medication use evaluation for deprescribing unnecessary chronic PPIs in elderly patients. The key patient-specific factors are long-term omeprazole use without current GERD symptoms, osteoporosis, and borderline vitamin B12 (260 pg/mL), with risks like fractures and deficiencies from prolonged PPI. Tapering and discontinuing with on-demand plan and rebound monitoring is the best choice to minimize exposure while preventing symptoms. Continuing indefinitely ignores risks; increasing dose lacks indication; switching to ranitidine is obsolete due to safety recalls. A clinical pearl is to reassess PPI need after 8-12 weeks; taper over 2-4 weeks to avoid rebound. In similar scenarios, evaluate indication and duration, monitor for adverse effects like bone density, and use H2 blockers or antacids as step-down.
13. A pharmacist performs an MUE for secondary prevention after myocardial infarction in a 63-year-old male (weight 84 kg) discharged 10 days ago with a drug-eluting stent. Discharge meds: aspirin 81 mg daily (adherent), clopidogrel 75 mg daily (misses ~2 doses/week due to cost), atorvastatin 80 mg nightly, and metoprolol succinate 50 mg daily; BP 126/74 mmHg. Labs: LDL 62 mg/dL (goal <70), SCr 1.0 mg/dL (0.6–1.2), hemoglobin 13.9 g/dL (13.5–17.5). The goal is to prevent stent thrombosis by ensuring uninterrupted dual antiplatelet therapy. What is the best strategy to improve patient adherence?
    Answer: Address cost barriers with a low-cost generic option, copay assistance, and refill synchronization; reinforce the importance of daily clopidogrel This question tests medication use evaluation for ensuring adherence to dual antiplatelet therapy post-myocardial infarction. The key patient-specific factors are recent drug-eluting stent, missed clopidogrel doses due to cost, controlled LDL (62 mg/dL), and goal of preventing thrombosis. Addressing cost with generics, assistance, synchronization, and reinforcement is the best choice to ensure uninterrupted therapy without altering regimen. Stopping clopidogrel risks stent thrombosis; switching to prasugrel ignores bleeding risks and cost; reducing to every other day compromises efficacy. A clinical pearl is that DAPT duration is typically 6-12 months post-stent; cost is a common barrier. In similar scenarios, review fill history, explore affordability options, and educate on consequences of nonadherence.
14. A health-system formulary change requires therapeutic interchange of an inhaled corticosteroid/long-acting beta-agonist (ICS/LABA). A 56-year-old female (weight 69 kg) with COPD (GOLD group D) is stable on fluticasone/salmeterol 250/50 mcg 1 inhalation twice daily (adherent) plus tiotropium 18 mcg daily; she had 1 exacerbation last year. The new formulary prefers budesonide/formoterol; SCr 0.9 mg/dL (0.6–1.2) and LFTs normal. The goal is to maintain symptom control and reduce exacerbations with an equivalent regimen. Which medication change is most appropriate to improve therapeutic outcomes?
    Answer: Switch to budesonide/formoterol 160/4.5 mcg 2 inhalations twice daily with inhaler education This question tests medication use evaluation for therapeutic interchange in COPD inhaler therapy under formulary changes. The key patient-specific factors are stable COPD on fluticasone/salmeterol 250/50 mcg twice daily (medium-high dose ICS/LABA), one prior exacerbation, and formulary preference for budesonide/formoterol. Switching to budesonide/formoterol 160/4.5 mcg 2 inhalations twice daily is the best choice as it provides equivalent ICS potency and LABA action to maintain control and reduce exacerbations. The 80/4.5 mcg once daily is underdosed; discontinuing ICS/LABA ignores guidelines; switching to scheduled albuterol lacks maintenance benefits. A clinical pearl is to match ICS doses for interchanges (e.g., fluticasone 250 mcg ≈ budesonide 320 mcg). In similar scenarios, confirm GOLD group, select equivalent potency, and educate on technique for seamless transitions.
15. A hospital pharmacist performing medication reconciliation at discharge evaluates a 72-year-old female (weight 62 kg) admitted for acute decompensated heart failure with reduced ejection fraction (HFrEF). Home meds per patient and fill history: lisinopril 20 mg PO daily (adherent), furosemide 40 mg PO daily (takes "as needed," ~3 days/week), metoprolol succinate 50 mg PO daily (adherent), and ibuprofen 600 mg PO three times daily for knee pain (daily use); inpatient course included IV diuresis and she is now euvolemic. Discharge labs: SCr 1.6 mg/dL (0.6–1.3), eGFR 32 mL/min/1.73 m$^2$ (≥60), K 5.3 mEq/L (3.5–5.0). Therapeutic goals are to prevent readmission and avoid worsening renal function/hyperkalemia. Which medication change is most appropriate to improve therapeutic outcomes?
    Answer: Stop ibuprofen and recommend acetaminophen as first-line for pain; reinforce scheduled furosemide dosing and arrange follow-up labs for SCr and potassium within 3–7 days This question evaluates medication reconciliation skills focusing on identifying and managing drug-disease interactions that worsen heart failure outcomes. The critical patient-specific factor is the daily use of ibuprofen 600 mg three times daily in a patient with HFrEF, reduced renal function (eGFR 32 mL/min/1.73 m²), and borderline hyperkalemia (K 5.3 mEq/L). Option B is the best intervention because NSAIDs like ibuprofen antagonize the effects of ACE inhibitors and diuretics, promote sodium/fluid retention, worsen renal function, and increase hyperkalemia risk - all of which can precipitate heart failure readmissions. Option A incorrectly continues the harmful NSAID and inappropriately increases furosemide, which doesn't address the underlying drug interaction. Option C is dangerous because adding spironolactone with potassium already at 5.3 mEq/L and reduced renal function could precipitate life-threatening hyperkalemia. Option D inappropriately doubles the ACE inhibitor dose with existing hyperkalemia and reduced renal function, which could worsen both parameters. The clinical framework is that NSAIDs should be avoided in heart failure patients, especially those with reduced renal function, and acetaminophen is the preferred analgesic for chronic pain management in this population.
16. A transitions-of-care pharmacist conducts medication reconciliation for a 64-year-old male (weight 90 kg) discharged after a transient ischemic attack (TIA). Pre-admission meds: aspirin 81 mg PO daily (adherent), simvastatin 20 mg PO nightly (adherent), omeprazole 20 mg PO daily (adherent). Discharge prescriptions include clopidogrel 75 mg PO daily and atorvastatin 80 mg PO daily; the patient states he will "keep taking everything I already have at home," including simvastatin and aspirin. Labs: AST 26 U/L (10–40), ALT 30 U/L (7–56), SCr 1.1 mg/dL (0.6–1.3). Which medication change is most appropriate to improve therapeutic outcomes?
    Answer: Stop simvastatin and use atorvastatin 80 mg daily as the single statin; confirm intended antiplatelet plan and provide clear written instructions to avoid duplicate therapy This question evaluates medication reconciliation skills focusing on therapeutic duplication and guideline-directed therapy optimization. The key patient-specific factor is discharge after TIA with two different statins prescribed (simvastatin 20 mg and atorvastatin 80 mg) plus the patient's intention to continue all medications including duplicates. Option B correctly identifies that high-intensity statin therapy (atorvastatin 80 mg) is guideline-recommended after TIA/stroke, making continuation of both statins inappropriate and potentially harmful due to increased myopathy risk without additional benefit. Option A dangerously suggests continuing dual statin therapy, which provides no additional LDL reduction beyond monotherapy while significantly increasing adverse effect risk. Option C incorrectly suggests stopping clopidogrel when short-term dual antiplatelet therapy (aspirin plus clopidogrel for 21-90 days) may be appropriate after minor stroke/TIA per current guidelines. Option D inappropriately returns to moderate-intensity statin therapy when high-intensity therapy is indicated for secondary prevention after cerebrovascular events. The clinical framework is that medication reconciliation must identify and resolve therapeutic duplications while ensuring patients receive guideline-directed intensity of therapy, with clear communication about which medications to stop and continue.
17. A health-system pharmacy and therapeutics (P&T) committee implements a formulary restriction removing esomeprazole; a 45-year-old female (weight 70 kg) with GERD and erosive esophagitis has been stable on esomeprazole 40 mg PO daily for 8 months with full adherence and no alarm symptoms. Current labs: SCr 0.8 mg/dL (0.6–1.3), AST 22 U/L (10–40), ALT 24 U/L (7–56); therapeutic goal is continued symptom control with an equivalent formulary agent. Which medication change is most appropriate to improve therapeutic outcomes?
    Answer: Substitute pantoprazole 40 mg PO daily as a therapeutically equivalent formulary proton pump inhibitor This question evaluates therapeutic interchange skills within formulary management for proton pump inhibitors. The key patient-specific factor is a stable patient on esomeprazole 40 mg daily for erosive esophagitis who requires conversion to an available formulary agent while maintaining therapeutic efficacy. Option A is correct because pantoprazole 40 mg daily provides equivalent acid suppression to esomeprazole 40 mg for erosive esophagitis, as all PPIs at standard doses achieve similar healing rates and symptom control when used appropriately. Option B incorrectly suggests famotidine 10 mg, which is an H2-receptor antagonist that provides inferior acid suppression compared to PPIs and is inadequate for erosive disease maintenance. Option C suggests an inadequate dose conversion, as omeprazole 10 mg is a half-standard dose and not equivalent to esomeprazole 40 mg for erosive disease. Option D inappropriately recommends discontinuing therapy in a patient with documented erosive disease who may require long-term maintenance to prevent complications. The clinical framework is that PPIs can be interchanged at equipotent doses: esomeprazole 40 mg = pantoprazole 40 mg = omeprazole 40 mg = lansoprazole 30 mg = rabeprazole 20 mg for erosive GERD maintenance.
18. A pharmacy manager reviews an MUE report showing increased emergency visits for hypoglycemia among older adults. One case is a 79-year-old female (weight 55 kg) with type 2 diabetes and CKD stage 3b taking glyburide 10 mg PO twice daily (adherent) and metformin 500 mg PO twice daily (adherent); she reports 3 episodes of shakiness and confusion in the past month with home glucose readings 48–62 mg/dL. Labs: A1c 6.4% (goal 7–8% individualized), SCr 1.8 mg/dL (0.6–1.3), eGFR 28 mL/min/1.73 m$^2$ (≥60). What is the best approach to optimize this patient's therapy?
    Answer: Discontinue glyburide and transition to a lower hypoglycemia-risk agent (e.g., linagliptin 5 mg PO daily), with relaxed glycemic targets and follow-up glucose monitoring This question tests recognition and management of medication-induced hypoglycemia in vulnerable populations. The critical patient-specific factors are an older adult (79 years) with CKD stage 3b (eGFR 28) experiencing recurrent hypoglycemia (glucose 48-62 mg/dL) while taking glyburide, a long-acting sulfonylurea contraindicated in severe renal impairment. Option B is the best approach because glyburide accumulates in renal dysfunction and causes prolonged hypoglycemia in older adults; switching to a DPP-4 inhibitor like linagliptin (no renal adjustment needed) with relaxed glycemic targets (A1c 7-8%) reduces hypoglycemia risk while maintaining appropriate control. Option A inappropriately adds another glucose-lowering agent when the patient is already experiencing hypoglycemia with an A1c below individualized goals. Option C dangerously suggests increasing glyburide, which would worsen hypoglycemia risk, and incorrectly states that tighter control is preferred in older adults when guidelines recommend relaxation of targets. Option D fails to address a serious safety issue, as recurrent hypoglycemia in older adults increases fall risk, cognitive decline, and cardiovascular events. The clinical pearl is that glyburide should be avoided in patients over 65 years or with CKD due to prolonged half-life and hypoglycemia risk, with newer agents providing safer alternatives.
19. A pharmacy management team reviews an MUE for chronic kidney disease (CKD) dosing in a 66-year-old male (weight 77 kg) with neuropathic pain. Medications: gabapentin 600 mg three times daily (adherent), metformin 500 mg twice daily, and losartan 50 mg daily. Labs: SCr 2.0 mg/dL (0.6–1.2), estimated creatinine clearance 28 mL/min, A1c 7.4% (goal <7%), and LFTs normal; he reports dizziness and daytime sedation. The goal is symptom control with minimized adverse effects through renal dose optimization. Which medication change is most appropriate to improve therapeutic outcomes?
    Answer: Reduce gabapentin dose and/or frequency based on renal function and reassess pain and sedation at follow-up This question tests the concept of medication use evaluation (MUE) focused on renal dose adjustments for medications in patients with chronic kidney disease to optimize safety and efficacy. The key patient-specific factor is the patient's reduced creatinine clearance of 28 mL/min, which impairs gabapentin clearance, leading to accumulation and adverse effects like dizziness and sedation at the current dose of 600 mg three times daily. Reducing the gabapentin dose and/or frequency based on renal function is the best choice as it minimizes adverse effects while maintaining pain control, with reassessment at follow-up to ensure therapeutic outcomes. Increasing the dose to 900 mg three times daily is incorrect as it would exacerbate accumulation and side effects without addressing tolerance, which is not typically an issue with gabapentin; continuing unchanged and adding diphenhydramine would worsen sedation and anticholinergic burden. Switching to pregabalin without renal adjustment is suboptimal because pregabalin also requires dose reduction in renal impairment, potentially leading to similar toxicity. A key clinical pearl is that for renally cleared drugs like gabapentin, always calculate estimated creatinine clearance using tools like Cockcroft-Gault and adjust doses per guidelines to prevent adverse events. In similar scenarios, prioritize dose optimization over adding new agents, incorporating patient-reported outcomes like sedation into decision-making frameworks for holistic care.
20. As part of an outpatient adverse-effect MUE, a 67-year-old female (weight 70 kg) with hyperlipidemia and hypothyroidism reports new diffuse muscle pain and weakness for 1 week. Medication history: simvastatin 40 mg nightly (adherent), amlodipine 10 mg daily, levothyroxine 75 mcg daily, and OTC ibuprofen as needed; no recent trauma. Labs: creatine kinase 980 U/L (30–200), AST 62 U/L (10–40), ALT 55 U/L (7–56), serum creatinine 1.0 mg/dL (0.6–1.2), TSH 2.1 mIU/L (0.4–4.0). Which medication change is most appropriate to improve therapeutic outcomes?
    Answer: Discontinue simvastatin and switch to pravastatin 40 mg nightly after symptoms resolve This question tests medication use evaluation for managing statin-induced myopathy and drug interactions in hyperlipidemia. The key patient-specific factors are new muscle pain, elevated CK (980 U/L) and liver enzymes, and the interaction between simvastatin 40 mg and amlodipine, which increases simvastatin exposure and myopathy risk. Discontinuing simvastatin and switching to pravastatin 40 mg after resolution is the best choice as pravastatin is not significantly affected by amlodipine and provides equivalent LDL lowering with lower myopathy risk. Continuing simvastatin with coenzyme Q10 lacks strong evidence for symptom relief and ignores the interaction; increasing to simvastatin 80 mg would worsen myopathy; stopping amlodipine eliminates the interaction but may compromise blood pressure control without alternatives. A clinical pearl is that simvastatin doses should be limited to 20 mg with amlodipine per guidelines. In similar scenarios, assess symptoms and labs, identify interactions, and select alternative statins like pravastatin or rosuvastatin, monitoring CK and symptoms post-switch.

Start this quiz